sorafenib has been researched along with palbociclib in 9 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 911 | 126 | 864 |
| Protein | Taxonomy | sorafenib (IC50) | palbociclib (IC50) |
|---|---|---|---|
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
| Cyclin-K | Homo sapiens (human) | 1.207 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
| Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Alba, GQ; Ayres, M; Carlson, TJ; Chen, A; Chen, X; Cho, R; Connors, RV; Dai, K; DeGraffenreid, M; Deignan, JT; Duquette, J; Eksterowicz, J; Fan, P; Fisher, B; Fu, J; Gribble, MW; Huard, JN; Kaizerman, J; Kamb, A; Keegan, KS; Li, C; Li, K; Li, Y; Li, Z; Liang, L; Liu, W; Lively, SE; Lo, MC; Ma, J; McGee, LR; McMinn, DL; Medina, JC; Mihalic, JT; Modi, K; Ngo, R; Pattabiraman, K; Piper, DE; Queva, C; Ragains, ML; Suchomel, J; Thibault, S; Walker, N; Wang, X; Wang, Z; Wanska, M; Wehn, PM; Weidner, MF; Wickramasinghe, D; Zhang, AJ; Zhao, X | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Alba, G; Carlson, T; Chen, A; Coberly, S; Dai, K; Eksterowicz, J; Hollenback, D; Huard, J; Kamb, A; Keegan, K; Li, C; Li, Z; Liang, L; Liu, L; Lo, MC; Ma, J; McGee, LR; Medina, J; Ngo, R; Orf, J; Quéva, C; Ragains, M; Wang, X; Weidner, M; Wickramasinghe, D; Zhao, S | 1 |
| Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
1 review(s) available for sorafenib and palbociclib
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
8 other study(ies) available for sorafenib and palbociclib
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.
Topics: Animals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dogs; Drug Discovery; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Macaca fascicularis; Naphthyridines; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship; U937 Cells | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Naphthyridines; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Drug Evaluation, Preclinical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Retinoblastoma Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases | 2017 |
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Humans; Mice; Neoplasm Recurrence, Local; Osteosarcoma; Piperazines; Pyridines; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |